$CMND

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

Clearmind Medicine (CMND) presented at an FDA hearing on psychedelic drugs, discussing patient access. The company's Chief of Global Impact shared insights from its MEAI clinical trial at Yale and Johns Hopkins, suggesting non-hallucinogenic treatments could expand access. CMND's stock is up 21.72% to $0.97.

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

Clearmind Medicine (CMND) shares fell 14% after it agreed to buy a 51% stake in Charging Robotics for $2.5M, including a $1.5M loan at 4% interest. CMND stock is trading at $1.45, down from $1.70.

Clearmind Medicine Inc. (Nasdaq: CMND) agreed to acquire a 51% stake in Charging Robotics, a wireless charging solutions provider for automated parking and robotaxis, for $2.5M. The deal includes a $1.5M loan at 4% interest. Closing is expected by September 7, 2026, subject to conditions. Charging Robotics' technology offers up to 10 kW continuous charging with smart vehicle communication.

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

Clearmind Medicine (CMND) announced a U.S. patent application for a novel MDMA-PEA combination for PTSD, anxiety, and eating disorders, a milestone from its collaboration with NeuroThera Labs. The FDA's recent psychedelic drug guidance includes MDMA, providing regulatory context for Clearmind's program. CMND's stock closed at $1.74, up 0.87%, and is currently trading at the same price in the pre-market.

SciSparc (SPRC) and Clearmind (CMND) advanced their MDMA-PEA patent for PTSD treatment. The U.S. FDA issued psychedelic drug guidance, aiding their development. SPRC and CMND traded at $6.70 and $1.74 respectively, with slight premarket declines.

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.